The national Minister of Health and provincial MECs limited the availability of the antiretroviral drug nevirapine in the public health sector to two designated pilot sites per province as part of a research and training programme to prevent mother-to-child transmission (MTCT) of HIV. Nevirapine had been registered as safe and effective, approved for MTCT prevention, and offered to government free of charge. Outside the pilot sites, public-sector doctors were prohibited from prescribing the drug, even where medically indicated. Civil society organisations, led by the Treatment Action Campaign, challenged this policy, arguing that it unreasonably restricted access to health care for HIV-positive pregnant women and their babies and that government failed to implement a comprehensive national MTCT prevention programme with clear timeframes.